Drug Profile
LBS 002
Alternative Names: LBS002Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator University of Sydney
- Developer Lin Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain cancer